| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phantoms, Imaging | 60 | 2023 | 1330 | 6.290 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 70 | 2023 | 2452 | 5.230 |
Why?
|
| Radiometry | 47 | 2022 | 1018 | 4.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 43 | 2023 | 2168 | 4.000 |
Why?
|
| Radiotherapy Dosage | 67 | 2023 | 4002 | 3.530 |
Why?
|
| Particle Accelerators | 20 | 2018 | 362 | 3.220 |
Why?
|
| Quality Assurance, Health Care | 24 | 2021 | 606 | 2.740 |
Why?
|
| Monte Carlo Method | 18 | 2021 | 697 | 2.690 |
Why?
|
| Radiation Oncology | 17 | 2021 | 557 | 2.450 |
Why?
|
| Radiation Dosage | 25 | 2020 | 1043 | 2.360 |
Why?
|
| Photons | 28 | 2022 | 537 | 2.270 |
Why?
|
| Head | 10 | 2020 | 248 | 1.900 |
Why?
|
| Credentialing | 10 | 2016 | 61 | 1.900 |
Why?
|
| Thorax | 6 | 2019 | 230 | 1.670 |
Why?
|
| Algorithms | 23 | 2020 | 3910 | 1.660 |
Why?
|
| Neck | 6 | 2020 | 386 | 1.420 |
Why?
|
| Proton Therapy | 9 | 2021 | 1638 | 1.360 |
Why?
|
| Radiotherapy, Image-Guided | 8 | 2020 | 338 | 1.240 |
Why?
|
| Thermoluminescent Dosimetry | 9 | 2019 | 74 | 1.210 |
Why?
|
| Neutrons | 9 | 2010 | 117 | 1.190 |
Why?
|
| Quality Control | 15 | 2023 | 466 | 1.130 |
Why?
|
| Calibration | 16 | 2021 | 346 | 1.130 |
Why?
|
| Radiotherapy | 14 | 2019 | 1858 | 1.080 |
Why?
|
| Health Physics | 4 | 2018 | 62 | 1.070 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2022 | 7783 | 1.030 |
Why?
|
| Clinical Trials as Topic | 15 | 2020 | 3862 | 1.030 |
Why?
|
| Artifacts | 6 | 2020 | 537 | 0.940 |
Why?
|
| Cancer Care Facilities | 4 | 2017 | 908 | 0.880 |
Why?
|
| Radiotherapy, High-Energy | 8 | 2014 | 303 | 0.870 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 7951 | 0.840 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2021 | 218 | 0.830 |
Why?
|
| Radiotherapy, Conformal | 11 | 2020 | 898 | 0.830 |
Why?
|
| Magnetic Fields | 2 | 2019 | 33 | 0.790 |
Why?
|
| Electrons | 6 | 2014 | 187 | 0.760 |
Why?
|
| Optically Stimulated Luminescence Dosimetry | 3 | 2018 | 21 | 0.740 |
Why?
|
| Film Dosimetry | 4 | 2019 | 62 | 0.720 |
Why?
|
| Lung | 10 | 2021 | 3267 | 0.680 |
Why?
|
| Models, Theoretical | 5 | 2019 | 804 | 0.650 |
Why?
|
| Head and Neck Neoplasms | 7 | 2020 | 4124 | 0.620 |
Why?
|
| Reproducibility of Results | 22 | 2019 | 6172 | 0.590 |
Why?
|
| Radiosurgery | 7 | 2020 | 1370 | 0.570 |
Why?
|
| Multicenter Studies as Topic | 4 | 2014 | 565 | 0.530 |
Why?
|
| Neoplasms | 18 | 2021 | 15849 | 0.500 |
Why?
|
| Organs at Risk | 7 | 2019 | 560 | 0.500 |
Why?
|
| Manikins | 1 | 2016 | 136 | 0.490 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2010 | 401 | 0.490 |
Why?
|
| Thoracic Neoplasms | 2 | 2008 | 347 | 0.480 |
Why?
|
| Equipment Design | 11 | 2020 | 1206 | 0.480 |
Why?
|
| Humans | 104 | 2022 | 270947 | 0.450 |
Why?
|
| Choroid Neoplasms | 3 | 2003 | 46 | 0.450 |
Why?
|
| Iridium Radioisotopes | 1 | 2013 | 57 | 0.450 |
Why?
|
| Clinical Protocols | 4 | 2018 | 480 | 0.380 |
Why?
|
| Brachytherapy | 5 | 2013 | 1005 | 0.380 |
Why?
|
| Clinical Audit | 2 | 2021 | 10 | 0.380 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 78 | 0.350 |
Why?
|
| Water | 5 | 2021 | 383 | 0.340 |
Why?
|
| Lung Neoplasms | 10 | 2018 | 11761 | 0.330 |
Why?
|
| Reference Standards | 6 | 2019 | 368 | 0.320 |
Why?
|
| Radiation Protection | 2 | 2007 | 205 | 0.310 |
Why?
|
| X-Rays | 4 | 2020 | 153 | 0.310 |
Why?
|
| Maximum Allowable Concentration | 1 | 2007 | 11 | 0.300 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 473 | 0.300 |
Why?
|
| Sensitivity and Specificity | 11 | 2016 | 5186 | 0.280 |
Why?
|
| Radiotherapy Setup Errors | 2 | 2017 | 85 | 0.280 |
Why?
|
| Feasibility Studies | 4 | 2020 | 2346 | 0.280 |
Why?
|
| Nanotechnology | 3 | 2018 | 137 | 0.270 |
Why?
|
| Research Report | 2 | 2019 | 143 | 0.260 |
Why?
|
| Pelvic Neoplasms | 1 | 2007 | 203 | 0.260 |
Why?
|
| Radiation Injuries | 3 | 2018 | 1472 | 0.250 |
Why?
|
| Cobalt Radioisotopes | 2 | 2014 | 41 | 0.240 |
Why?
|
| Immobilization | 2 | 2017 | 91 | 0.230 |
Why?
|
| Whole-Body Irradiation | 3 | 2021 | 324 | 0.230 |
Why?
|
| Models, Biological | 6 | 2012 | 3226 | 0.210 |
Why?
|
| Uncertainty | 6 | 2018 | 326 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2426 | 0.210 |
Why?
|
| Societies, Scientific | 2 | 2014 | 69 | 0.210 |
Why?
|
| Software | 6 | 2015 | 1361 | 0.200 |
Why?
|
| Colon | 3 | 2005 | 689 | 0.200 |
Why?
|
| Tinea Capitis | 1 | 2000 | 6 | 0.190 |
Why?
|
| Melanoma | 4 | 2012 | 5523 | 0.180 |
Why?
|
| United States | 12 | 2021 | 15983 | 0.170 |
Why?
|
| Scattering, Radiation | 6 | 2010 | 334 | 0.170 |
Why?
|
| Radiobiology | 1 | 2020 | 56 | 0.170 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 5990 | 0.170 |
Why?
|
| Liver | 3 | 2020 | 3126 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2010 | 6837 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2011 | 1150 | 0.160 |
Why?
|
| Metals | 2 | 2016 | 148 | 0.160 |
Why?
|
| Benchmarking | 3 | 2016 | 284 | 0.160 |
Why?
|
| Computer Simulation | 7 | 2018 | 1522 | 0.160 |
Why?
|
| Patient Positioning | 2 | 2019 | 195 | 0.160 |
Why?
|
| Medical Audit | 1 | 2019 | 196 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2018 | 81 | 0.160 |
Why?
|
| ROC Curve | 3 | 2019 | 1221 | 0.150 |
Why?
|
| Texas | 4 | 2016 | 6415 | 0.150 |
Why?
|
| Equipment Failure Analysis | 5 | 2011 | 327 | 0.140 |
Why?
|
| Pacemaker, Artificial | 1 | 2019 | 202 | 0.140 |
Why?
|
| Research Design | 3 | 2016 | 1568 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2017 | 2034 | 0.140 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 226 | 0.140 |
Why?
|
| Jurisprudence | 1 | 2016 | 19 | 0.140 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 1997 | 127 | 0.140 |
Why?
|
| Heart | 2 | 2020 | 1211 | 0.130 |
Why?
|
| Rectum | 2 | 2016 | 479 | 0.130 |
Why?
|
| Dental Amalgam | 1 | 2015 | 8 | 0.130 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hip Prosthesis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Poverty | 1 | 2018 | 477 | 0.120 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 280 | 0.120 |
Why?
|
| Movement | 2 | 2016 | 561 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 420 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2017 | 5517 | 0.120 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.120 |
Why?
|
| Palladium | 2 | 2012 | 56 | 0.120 |
Why?
|
| Fracture Fixation, Internal | 1 | 2015 | 94 | 0.120 |
Why?
|
| Spine | 1 | 2016 | 311 | 0.120 |
Why?
|
| Time Factors | 7 | 2018 | 13112 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2017 | 1433 | 0.120 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2015 | 210 | 0.120 |
Why?
|
| Australia | 1 | 2014 | 249 | 0.120 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2014 | 55 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2016 | 551 | 0.110 |
Why?
|
| Motion | 2 | 2015 | 200 | 0.110 |
Why?
|
| Acromegaly | 1 | 2013 | 28 | 0.110 |
Why?
|
| Optic Chiasm | 1 | 2013 | 42 | 0.110 |
Why?
|
| Advisory Committees | 2 | 2014 | 210 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 5904 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2014 | 241 | 0.110 |
Why?
|
| Collagen | 2 | 1995 | 738 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 740 | 0.110 |
Why?
|
| Professional Practice Location | 1 | 2012 | 14 | 0.110 |
Why?
|
| Child | 12 | 2022 | 30418 | 0.100 |
Why?
|
| Optics and Photonics | 1 | 2013 | 163 | 0.100 |
Why?
|
| Protons | 2 | 2017 | 483 | 0.100 |
Why?
|
| Optical Phenomena | 1 | 2012 | 26 | 0.100 |
Why?
|
| Professional Practice | 1 | 2012 | 81 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2014 | 420 | 0.100 |
Why?
|
| Shoulder | 1 | 2012 | 50 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1318 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 379 | 0.100 |
Why?
|
| Male | 20 | 2022 | 128454 | 0.100 |
Why?
|
| Optical Devices | 1 | 2011 | 11 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 528 | 0.100 |
Why?
|
| Anthropometry | 2 | 2014 | 264 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 218 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2022 | 39694 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 261 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 160 | 0.090 |
Why?
|
| Urology | 1 | 2012 | 138 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 305 | 0.090 |
Why?
|
| Eye | 1 | 2012 | 287 | 0.090 |
Why?
|
| Prostate | 1 | 2016 | 1139 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2012 | 259 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2000 | 1894 | 0.090 |
Why?
|
| Precision Medicine | 2 | 2015 | 1201 | 0.090 |
Why?
|
| Radiation Monitoring | 1 | 2009 | 53 | 0.080 |
Why?
|
| Iodine Radioisotopes | 3 | 2012 | 388 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 187 | 0.080 |
Why?
|
| Anisotropy | 1 | 2008 | 171 | 0.080 |
Why?
|
| Psychometrics | 1 | 2013 | 963 | 0.080 |
Why?
|
| Adenoma | 1 | 2013 | 741 | 0.080 |
Why?
|
| Radiography | 1 | 2013 | 1990 | 0.080 |
Why?
|
| Research | 1 | 2010 | 426 | 0.080 |
Why?
|
| International Agencies | 2 | 2019 | 106 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 1178 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 663 | 0.070 |
Why?
|
| Gene Expression | 1 | 1995 | 3681 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2007 | 749 | 0.070 |
Why?
|
| Biomimetic Materials | 1 | 2007 | 39 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 2669 | 0.070 |
Why?
|
| Eye Enucleation | 2 | 2003 | 87 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 1708 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2012 | 1347 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 805 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 10250 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 1913 | 0.060 |
Why?
|
| Gold | 2 | 2007 | 266 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 2899 | 0.060 |
Why?
|
| Carcinoma | 1 | 2016 | 2627 | 0.060 |
Why?
|
| Choroidal Neovascularization | 1 | 2004 | 31 | 0.060 |
Why?
|
| Risk | 1 | 2009 | 1914 | 0.060 |
Why?
|
| Female | 15 | 2022 | 148509 | 0.060 |
Why?
|
| Mice, Inbred C3H | 2 | 1995 | 400 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2022 | 16978 | 0.050 |
Why?
|
| Fast Neutrons | 1 | 2003 | 13 | 0.050 |
Why?
|
| Macular Degeneration | 1 | 2004 | 122 | 0.050 |
Why?
|
| Elementary Particles | 1 | 2003 | 24 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2019 | 2851 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 1093 | 0.050 |
Why?
|
| Software Validation | 2 | 2013 | 34 | 0.050 |
Why?
|
| Adolescent | 5 | 2022 | 32577 | 0.050 |
Why?
|
| Safety | 2 | 2019 | 466 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1955 | 0.050 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 16186 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 31 | 0.050 |
Why?
|
| Israel | 1 | 2000 | 59 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 2670 | 0.050 |
Why?
|
| Head Movements | 1 | 2000 | 26 | 0.050 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 1157 | 0.050 |
Why?
|
| Uveal Neoplasms | 1 | 2003 | 192 | 0.050 |
Why?
|
| Infant | 3 | 2022 | 13913 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 6982 | 0.050 |
Why?
|
| Respiration | 2 | 2015 | 465 | 0.050 |
Why?
|
| Postal Service | 1 | 2020 | 15 | 0.040 |
Why?
|
| Nuclear Energy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Peer Review | 1 | 2020 | 82 | 0.040 |
Why?
|
| Organizational Objectives | 2 | 2014 | 68 | 0.040 |
Why?
|
| Medical Errors | 2 | 2017 | 225 | 0.040 |
Why?
|
| Mice | 6 | 2020 | 35992 | 0.040 |
Why?
|
| Thiotepa | 1 | 2019 | 132 | 0.040 |
Why?
|
| Stomach | 2 | 2016 | 406 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4788 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2018 | 54 | 0.040 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 1486 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 658 | 0.040 |
Why?
|
| Spinal Cord | 2 | 2016 | 726 | 0.040 |
Why?
|
| Phenylpropionates | 1 | 2017 | 17 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 1379 | 0.030 |
Why?
|
| Etoposide | 1 | 2019 | 905 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 325 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2003 | 1934 | 0.030 |
Why?
|
| Radiation Dosimeters | 1 | 2016 | 8 | 0.030 |
Why?
|
| Rubber | 1 | 2015 | 6 | 0.030 |
Why?
|
| Plant Structures | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 1995 | 9 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 1106 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 15253 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 1995 | 38 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2016 | 102 | 0.030 |
Why?
|
| Tensile Strength | 1 | 1995 | 74 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 291 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5233 | 0.030 |
Why?
|
| Animals | 6 | 2020 | 62771 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 78 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 360 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 2314 | 0.030 |
Why?
|
| Aged | 6 | 2018 | 73161 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2014 | 28 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2018 | 13352 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2016 | 2434 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 126 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 1153 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2018 | 426 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 201 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2016 | 599 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 1062 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2001 | 790 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 4505 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 621 | 0.030 |
Why?
|
| Industry | 1 | 2013 | 51 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 622 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 30941 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 725 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 550 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3645 | 0.030 |
Why?
|
| Group Practice | 1 | 2012 | 18 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2012 | 48 | 0.030 |
Why?
|
| Fibrosis | 1 | 1995 | 744 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 1445 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2018 | 701 | 0.030 |
Why?
|
| Ownership | 1 | 2012 | 42 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 410 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1820 | 0.030 |
Why?
|
| Intestines | 1 | 2016 | 731 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 916 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 349 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 3231 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 1993 | 222 | 0.020 |
Why?
|
| Adult | 4 | 2022 | 81555 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2289 | 0.020 |
Why?
|
| Clavicle | 1 | 2010 | 66 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 55 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 671 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 989 | 0.020 |
Why?
|
| Risk Factors | 1 | 2007 | 17824 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 644 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 875 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 22059 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 2359 | 0.020 |
Why?
|
| Middle Aged | 5 | 2017 | 90021 | 0.020 |
Why?
|
| X-Ray Film | 1 | 2009 | 31 | 0.020 |
Why?
|
| Periodicity | 1 | 2009 | 71 | 0.020 |
Why?
|
| Forecasting | 2 | 2003 | 707 | 0.020 |
Why?
|
| Leukemia | 1 | 2018 | 1720 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 2048 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8591 | 0.020 |
Why?
|
| Bleomycin | 1 | 1990 | 470 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 2804 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1993 | 1124 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6248 | 0.020 |
Why?
|
| Sarcoma | 1 | 2018 | 1840 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4968 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 22458 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 753 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5324 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 7813 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1990 | 751 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3142 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 2004 | 156 | 0.010 |
Why?
|
| Photography | 1 | 2004 | 127 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2005 | 751 | 0.010 |
Why?
|
| Ruthenium Radioisotopes | 1 | 2003 | 8 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2005 | 370 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2003 | 176 | 0.010 |
Why?
|
| Esophagus | 1 | 2005 | 563 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 13976 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 919 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 120 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2004 | 873 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 10349 | 0.010 |
Why?
|
| Polystyrenes | 1 | 1998 | 36 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1998 | 117 | 0.010 |
Why?
|
| Biophysics | 1 | 1998 | 116 | 0.010 |
Why?
|
| Plastics | 1 | 1998 | 97 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2005 | 1462 | 0.010 |
Why?
|
| Temperature | 1 | 1998 | 541 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 2247 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 4983 | 0.010 |
Why?
|
| Plethysmography, Whole Body | 1 | 1990 | 8 | 0.010 |
Why?
|
| Leukemia P388 | 1 | 1990 | 28 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 4257 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 570 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 9043 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1990 | 536 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1990 | 255 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2004 | 33827 | 0.000 |
Why?
|